SABS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
SAB Biotherapeutics Inc (SABS) is not a strong buy for a beginner, long-term investor at this moment. The company's financial performance is poor, hedge funds are selling, and there are no strong technical or proprietary trading signals supporting an immediate entry. While analysts have a positive outlook with increased price targets, the lack of recent news catalysts, weak technical indicators, and poor financials suggest holding off for now.
The MACD histogram is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 43.856, and moving averages are converging, showing no clear trend. Key support is at 3.705, and resistance is at 4.49. The stock is trading near support levels but lacks strong bullish signals.
Analysts have raised the price target to $14, citing promising Phase I trial data for SAB-142 as a treatment for type I diabetes. Additionally, the stock has a 70% chance of gaining 4.15% in the next week and 9.33% in the next month.
Hedge funds are heavily selling, with a 10058566.67% increase in selling activity over the last quarter. The company's financials are extremely poor, with revenue, net income, EPS, and gross margin all significantly declining YoY. No recent news or congress trading data is available to support a positive sentiment.
In Q4 2025, revenue dropped to 0 (-100% YoY), net income fell to -$2,845,412 (-75.03% YoY), EPS declined to -$0.06 (-95.12% YoY), and gross margin dropped to 0 (-100% YoY). The financials indicate severe underperformance.
Chardan raised the price target to $14 from $12 and maintained a Buy rating, citing promising Phase I trial data for SAB-142. UBS initiated coverage with a Buy rating and a $7 price target, highlighting the company's strong data and broader pipeline. However, the positive outlook is tempered by the small sample size of the trial data.
